Allena pharmaceuticals, inc. (ALNA)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Sep'16
Operating expenses:
Research and development

4,646

8,721

10,806

8,589

9,128

7,269

7,316

5,860

5,931

4,761

2,949

3,458

4,351

5,263

General and administrative

2,878

1,967

2,532

2,746

2,431

2,511

2,389

2,275

2,042

1,810

1,413

1,017

1,191

839

Total operating expenses

7,524

11,293

13,338

11,335

11,559

9,780

9,705

8,135

7,973

-

4,362

4,475

-

-

Total operating expenses

-

-

-

-

-

-

-

-

-

-

-

-

5,542

6,102

Loss from operations

-7,524

-

-13,338

-11,335

-11,559

-

-9,705

-8,135

-7,973

-

-4,362

-4,475

-5,542

-6,102

Other income (expense):
Interest income (expense), net

-54

-12

53

78

151

177

180

118

100

-42

-146

-123

-132

-42

Other expense, net

-

-

-

16

-

-

-

13

7

-

-

-

-

-

Other expense, net

-7

-

-3

-

-11

-

15

-

-

-64

-162

-34

3

8

Loss on extinguishment of debt

-

-

-

-

-

-

-

-617

-

-

-

-

-

-

Other income (expense), net

-61

-66

50

62

140

169

195

-512

93

-106

-308

-157

-129

-34

Net loss

-7,585

-11,359

-13,288

-11,273

-11,419

-9,611

-9,510

-8,647

-7,880

-6,677

-4,670

-4,632

-5,671

-6,136

Net loss per share attributable to common stockholders—basic and diluted

-0.31

-0.47

-0.57

-0.54

-0.55

-0.46

-0.46

-0.42

-0.38

6.39

-3.49

-3.46

-4.24

-4.59

Weighted-average common shares outstanding—basic and diluted

24,737

23,540

23,464

20,903

20,814

20,783

20,753

20,733

20,695

14,052

1,343

1,342

1,342

1,341

Net loss

-7,585

-11,359

-13,288

-11,273

-11,419

-9,611

-9,510

-8,647

-7,880

-6,677

-4,670

-4,632

-5,671

-6,136

Unrealized loss on investments

-

-

-

-

-

-

-

-

-

-

0

3

-1

-

Total other comprehensive loss

-

-

-

-

-

-

-

-

-

-

0

3

-1

-

Comprehensive loss

-7,585

-11,359

-13,288

-11,273

-11,419

-9,611

-9,510

-8,647

-7,880

-6,679

-4,670

-4,629

-5,672

-6,136